Welcome to our dedicated page for Pediatrix Medical Group news (Ticker: MD), a resource for investors and traders seeking the latest updates and insights on Pediatrix Medical Group stock.
Pediatrix Medical Group, Inc. provides specialized physician services in neonatal intensive care, maternal-fetal medicine, and pediatric subspecialties. This news hub offers investors and healthcare stakeholders centralized access to official announcements and material developments impacting this niche medical services provider.
Discover up-to-date press releases covering financial results, clinical quality initiatives, and hospital partnership expansions. Our curated collection includes updates on evidence-based care advancements, leadership changes, and operational milestones relevant to neonatal/pediatric healthcare delivery.
This resource serves investors requiring timely MD updates and medical professionals tracking care innovations. All content maintains factual accuracy without speculative commentary, aligning with regulatory standards for financial disclosures.
Bookmark this page for efficient tracking of Pediatrix Medical Group's strategic developments in high-risk obstetric and neonatal care markets. Verify critical updates through primary sources when making data-driven decisions.
Pediatrix Medical Group (NYSE: MD) has announced its upcoming first quarter 2025 investor conference call and webcast, scheduled for Tuesday, May 6, 2025, at 9:00 a.m. ET. The company will discuss its operational results for the quarter ending March 31, 2025.
A detailed press release will be issued before market opening on May 6, 2025. Investors and interested parties can access the webcast through the company's investor relations website at www.pediatrix.com/investors.
Pediatrix Medical Group (NYSE: MD) reported strong Q4 2024 results with net revenue of $502.4 million, up from $496.4 million in the prior year. The company achieved net income of $30.5 million, or $0.36 per share, compared to a net loss of $124.3 million in Q4 2023. Adjusted EPS reached $0.51, up from $0.32 year-over-year.
Same-unit revenue grew 8.7%, driven by a 5.9% increase in net reimbursement-related factors and 2.8% growth in patient volume. The company completed its portfolio restructuring, exiting office-based practices and primary/urgent care service lines that generated approximately $200 million in 2023 revenue. Adjusted EBITDA increased to $68.7 million from $50.8 million in the prior year.
The company's financial position strengthened with cash and cash equivalents of $229.9 million, up from $73.3 million at the end of 2023. For 2025, Pediatrix projects Adjusted EBITDA between $215-235 million.
Pediatrix Medical Group (NYSE: MD) has announced NEO: The Conference for Neonatology, a major educational event scheduled for Feb. 19-21 in Las Vegas. The conference aims to advance neonatology by bringing together neonatologists, pediatricians, and healthcare professionals globally.
The announcement comes as the March of Dimes' 2024 Report Card reveals concerning statistics about preterm births in the United States. The nation's preterm birth rate remains at a historic high of 10.4%, with 370,000 premature births in 2023, only slightly lower than the 10.5% rate in 2022. The U.S. received a D+ grade for the third consecutive year.
As a leading provider of neonatology services for over 45 years, Pediatrix currently cares for nearly 25% of U.S. infants requiring intensive care. Dr. Timothy Biela, conference director and neonatologist at Pediatrix Neonatology of San Antonio, emphasizes the critical need for continuous innovation in neonatal-perinatal medicine to improve outcomes for vulnerable patients.
Pediatrix Medical Group (NYSE: MD) has announced its upcoming fourth quarter 2024 investor conference call and webcast, scheduled for Thursday, February 20, 2025, at 9:00 a.m. ET. The company will discuss its operational results for the quarter ending December 31, 2024.
A comprehensive press release containing detailed information will be issued before market opening on February 20, 2025. Investors and interested parties can access the webcast through the company's investor relations website at www.pediatrix.com/investors.
Pediatrix Medical Group (NYSE: MD) announced a significant leadership change, with Executive Chair Mark S. Ordan returning as Chief Executive Officer, effective immediately. The transition aims to accelerate the company's transformational strategy focused on clinical excellence and strengthening hospital relationships.
The company has implemented several key initiatives in the past year, including transitioning to a hybrid revenue cycle management model, optimizing practice portfolios, divesting primary and urgent care clinics, and restructuring leadership. James D. Swift, M.D., who became CEO in January 2023, will assist during the transition.
Regarding financial outlook, Pediatrix expects to achieve the high end of its previously announced 2024 adjusted EBITDA range of $205-215 million, with potential to exceed this range. The company will announce its Q4 and full-year 2024 results on February 20, 2025.
Pediatrix Medical Group (NYSE: MD) reported third quarter 2024 results with net revenue of $511.2 million, up from $506.6 million in the prior year. The company achieved net income of $19.4 million, or $0.23 per share, compared to $21.4 million ($0.26 per share) in Q3 2023. Same-unit revenue grew 5.2%, driven by a 3.4% increase in reimbursement-related factors and 1.8% growth in patient volume. Adjusted EBITDA reached $60.2 million, up from $50.4 million year-over-year. The company maintains its 2024 Adjusted EBITDA guidance of $205-215 million.
Pediatrix Medical Group (NYSE: MD) has announced its upcoming investor conference call and webcast, scheduled for Friday, November 1, 2024, at 9:00 a.m. ET. The event will focus on discussing the company's operational results for the quarter ending September 30, 2024.
A comprehensive press release detailing the results will be issued on the morning of November 1, 2024, prior to the opening of the securities markets. Investors and interested parties can access the conference call and webcast through the company's official website at www.pediatrix.com/investors.
This announcement provides an opportunity for stakeholders to gain insights into Pediatrix Medical Group's financial performance and operational achievements for the third quarter of 2024.
Pediatrix Medical Group (NYSE: MD) reported a loss of $1.84 per share for Q2 2024, with Adjusted EPS of $0.34. Key results include:
- Net revenue: $504 million
- Net loss: $153 million
- Adjusted EBITDA: $58 million
The company saw 2.8% same-unit revenue growth, improved payor mix, and stable patient volumes. Pediatrix is implementing portfolio management plans, exiting most office-based practices except maternal-fetal medicine. The company expects these changes to have a $30 million favorable impact on Adjusted EBITDA. Pediatrix maintains its 2024 Adjusted EBITDA outlook of $200-$220 million.
Pediatrix Medical Group (NYSE: MD) has announced its upcoming 2024 Second Quarter Conference Call and Webcast, scheduled for Tuesday, August 6, 2024, at 9:00 a.m. ET. The event will focus on discussing the company's operational results for the quarter ending June 30, 2024.
Investors and interested parties can access the webcast through Pediatrix's official website at www.pediatrix.com/investors. A detailed press release containing the quarterly results will be issued on the morning of August 6, 2024, before the securities markets open, providing stakeholders with comprehensive information prior to the call.
Pediatrix Medical Group (NYSE: MD) announced its participation in two upcoming healthcare investor conferences. The company will present at the Leerink Partners Healthcare Crossroads Conference in Austin, TX, on May 30, 2024, at 9:20 am CT, followed by the Jefferies Global Healthcare Conference in New York, NY, on June 6, 2024, at 7:30 am ET. Both events are anticipated to provide insights into Pediatrix's business strategies and growth prospects. Investors can access audio webcasts of these presentations on Pediatrix's website.
